TY - JOUR
T1 - What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
AU - Passiglia, Francesco
AU - Cajozzo, Massimo
AU - Fiorentino, Eugenio
AU - Bronte, Giuseppe
AU - Russo, Antonio
AU - Gil-Bazo, Ignacio
AU - Russo, Antonio
AU - Passiglia, Francesco
AU - Fiorentino, Eugenio
AU - Pauwels, Patrick
AU - Rolfo, Christian
AU - Cajozzo, Massimo
AU - Van Meerbeeck, Jan P.
AU - Lequaglie, Cosimo
AU - Rizzo, Sergio
AU - Santini, Daniele
AU - Bronte, Giuseppe
AU - Rolfo, Christian Diego
AU - Rizzo, Sergio
PY - 2015
Y1 - 2015
N2 - BackgroundRandomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.Materials and methodsData from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities.ResultsSix eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group.ConclusionThis meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
AB - BackgroundRandomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.Materials and methodsData from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities.ResultsSix eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group.ConclusionThis meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
UR - http://hdl.handle.net/10447/157384
M3 - Article
SN - 1879-0461
VL - 95
SP - 306
EP - 317
JO - CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY
JF - CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY
ER -